Find and Pitch Jounalists, Get Your Story Covered

Tags: Emerging Therapies Momelotinib Myelofibrosis Pharmacists Anemia

	Profile	Recent Articles on Subject
1	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 4 days ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 6 months ago
2	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Exploratory Analysis Shows Favorable Outcomes for Amivantamab-Lazertinib Treatment in NSCLC - 7 days ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - about 1 month ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - about 1 month ago FDA Approves Rybrevant as First-Line Treatment for NSCLC - 7 months ago FDA Approves Osimertinib With Chemotherapy for EGFRm NSCLC - 7 months ago FDA Grants Accelerated Approval to Lifileucel For Treatment of Advanced Melanoma - 7 months ago FDA Grants Orphan Drug Designation to Tigilanol Tiglate for Soft Tissue Sarcoma - 7 months ago FDA Approves Belzutifan for Treatment of Advanced Renal Cell Carcinoma - 9 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 10 months ago FDA Approves Repotrectinib for Treatment of ROS1-Positive NSCLC - 10 months ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - 11 months ago FDA Grants Priority Review to New Drug Application for Belzutifan for Advanced Renal Cell Carcinoma - 12 months ago
3	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 8 days ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - about 1 month ago FDA OKs First Cellular Therapy for Melanoma - 7 months ago FDA Approves Belzutifan for Advanced Renal Cell Carcinoma - 9 months ago Osimertinib Shows Activity in NSCLC With Uncommon EGFR Mutations - 10 months ago FDA OKs New Option for Advanced ROS1-Positive Lung Cancer - 10 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - 11 months ago RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer - 11 months ago RET Inhibitor Posts Frontline Wins in Medullary Thyroid Cancer, NSCLC - 11 months ago
4	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Grants Regenerative Medicine Advanced Therapy Designation for OBX-115 - 15 days ago Utidelone Injectable Granted FDA Orphan Drug Designation for Breast Cancer Brain Metastasis - 6 months ago Osimertinib With Chemotherapy Could Aid Overall Survival for NSCLC - 6 months ago
5	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma - 3 months ago TIL Therapy May Offer Novel Approach for Metastatic Lung Cancer - 3 months ago Novel TKI Promising in Early Study of HER2-Mutant NSCLC - 3 months ago Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma - 8 months ago Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T - 8 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 9 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 9 months ago Novel Doublet Highly Effective in Low-Grade Serous Ovarian Cancer - 10 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 10 months ago
6	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Geron Drug Lands a First-in-Class FDA Approval in Type of Blood Cancer - 3 months ago
7	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 7 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 9 months ago Lenvatinib-Pembrolizumab Combo Misses Goal in First-Line HCC Trial - 9 months ago Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia - 9 months ago Non-Covalent BTK Inhibitor Approved for CLL - 10 months ago New Oral Drug Approved for Metastatic Colorectal Cancer - 11 months ago New Options Challenge Standard Treatments in EGFR-Mutant NSCLC - 11 months ago Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years - 11 months ago
8	Erin Hunter, Associate Editor Pharmacy Times Actor-writer. Nominated BBC Popcorn. London, United Kingdom actingwritingcomedy	FDA Accepts BLA for Datopotamab Deruxtecan for the Treatment of NSCLC - 7 months ago FDA Grants Priority Review to Repotrectinib for the Treatment of NTRK-Positive Solid Tumors - 7 months ago
9	Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. PoliticsStorytellingCats	FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Therapies - 8 months ago New Capivasertib Approval Benefits Patients With Breast Cancer, PIK3CA/AKT1/PTEN Alterations - 10 months ago FDA Experts Review Data, Regulatory Insights for New Metastatic Breast Cancer Treatments - 10 months ago
10	Pharmaceutical Executive Editorial Staff Pharmaceutical Executive Pharma Executive Magazine. London & New Jersey PharmaceuticalsHealthcare	Novartis Announces Positive Findings for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia - 9 months ago Erasca’s Naporafenib Gets FDA Fast Track Designation for Metastatic Melanoma - 9 months ago

Journalists covering Momelotinib